TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Wednesday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TherapeuticsMD stock opened at $1.88 on Wednesday. The stock’s 50-day simple moving average is $2.20 and its 200-day simple moving average is $2.28. TherapeuticsMD has a 52 week low of $1.85 and a 52 week high of $4.73.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC acquired a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned about 0.21% of TherapeuticsMD at the end of the most recent reporting period. Institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.